Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15871635rdf:typepubmed:Citationlld:pubmed
pubmed-article:15871635lifeskim:mentionsumls-concept:C0376387lld:lifeskim
pubmed-article:15871635lifeskim:mentionsumls-concept:C0029216lld:lifeskim
pubmed-article:15871635lifeskim:mentionsumls-concept:C0524930lld:lifeskim
pubmed-article:15871635lifeskim:mentionsumls-concept:C0440790lld:lifeskim
pubmed-article:15871635lifeskim:mentionsumls-concept:C0001563lld:lifeskim
pubmed-article:15871635lifeskim:mentionsumls-concept:C0033262lld:lifeskim
pubmed-article:15871635lifeskim:mentionsumls-concept:C0017066lld:lifeskim
pubmed-article:15871635lifeskim:mentionsumls-concept:C0909381lld:lifeskim
pubmed-article:15871635lifeskim:mentionsumls-concept:C1979963lld:lifeskim
pubmed-article:15871635lifeskim:mentionsumls-concept:C2003903lld:lifeskim
pubmed-article:15871635lifeskim:mentionsumls-concept:C0201734lld:lifeskim
pubmed-article:15871635pubmed:issue5lld:pubmed
pubmed-article:15871635pubmed:dateCreated2005-5-5lld:pubmed
pubmed-article:15871635pubmed:abstractTextValganciclovir (Valcyte) has recently been approved for the prevention of cytomegalovirus (CMV) disease in high-risk (CMV donor positive [D+]/recipient negative [R-]) solid organ transplant (SOT) recipients. Large-scale studies describing the pharmacokinetics of valganciclovir in SOT recipients are lacking. A recent randomised, double-blind study of valganciclovir in 364 D+/R- (intent-to-treat population) SOT recipients provided valuable data on which a population pharmacokinetic analysis was performed.lld:pubmed
pubmed-article:15871635pubmed:languageenglld:pubmed
pubmed-article:15871635pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15871635pubmed:citationSubsetIMlld:pubmed
pubmed-article:15871635pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15871635pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15871635pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15871635pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15871635pubmed:statusMEDLINElld:pubmed
pubmed-article:15871635pubmed:issn0312-5963lld:pubmed
pubmed-article:15871635pubmed:authorpubmed-author:HumarAtulAlld:pubmed
pubmed-article:15871635pubmed:authorpubmed-author:WiltshireHugh...lld:pubmed
pubmed-article:15871635pubmed:authorpubmed-author:HeatonNigelNlld:pubmed
pubmed-article:15871635pubmed:authorpubmed-author:BlumbergEmily...lld:pubmed
pubmed-article:15871635pubmed:authorpubmed-author:PescovitzMark...lld:pubmed
pubmed-article:15871635pubmed:authorpubmed-author:PayaCarlosClld:pubmed
pubmed-article:15871635pubmed:authorpubmed-author:AlexanderBarb...lld:pubmed
pubmed-article:15871635pubmed:authorpubmed-author:FreemanRichar...lld:pubmed
pubmed-article:15871635pubmed:authorpubmed-author:WashburnKenne...lld:pubmed
pubmed-article:15871635pubmed:authorpubmed-author:Valganciclovi...lld:pubmed
pubmed-article:15871635pubmed:authorpubmed-author:HirankarnSara...lld:pubmed
pubmed-article:15871635pubmed:authorpubmed-author:FarrellColmClld:pubmed
pubmed-article:15871635pubmed:authorpubmed-author:DominguezEdwa...lld:pubmed
pubmed-article:15871635pubmed:issnTypePrintlld:pubmed
pubmed-article:15871635pubmed:volume44lld:pubmed
pubmed-article:15871635pubmed:ownerNLMlld:pubmed
pubmed-article:15871635pubmed:authorsCompleteYlld:pubmed
pubmed-article:15871635pubmed:pagination495-507lld:pubmed
pubmed-article:15871635pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15871635pubmed:meshHeadingpubmed-meshheading:15871635...lld:pubmed
pubmed-article:15871635pubmed:meshHeadingpubmed-meshheading:15871635...lld:pubmed
pubmed-article:15871635pubmed:meshHeadingpubmed-meshheading:15871635...lld:pubmed
pubmed-article:15871635pubmed:meshHeadingpubmed-meshheading:15871635...lld:pubmed
pubmed-article:15871635pubmed:meshHeadingpubmed-meshheading:15871635...lld:pubmed
pubmed-article:15871635pubmed:meshHeadingpubmed-meshheading:15871635...lld:pubmed
pubmed-article:15871635pubmed:meshHeadingpubmed-meshheading:15871635...lld:pubmed
pubmed-article:15871635pubmed:meshHeadingpubmed-meshheading:15871635...lld:pubmed
pubmed-article:15871635pubmed:meshHeadingpubmed-meshheading:15871635...lld:pubmed
pubmed-article:15871635pubmed:meshHeadingpubmed-meshheading:15871635...lld:pubmed
pubmed-article:15871635pubmed:meshHeadingpubmed-meshheading:15871635...lld:pubmed
pubmed-article:15871635pubmed:meshHeadingpubmed-meshheading:15871635...lld:pubmed
pubmed-article:15871635pubmed:meshHeadingpubmed-meshheading:15871635...lld:pubmed
pubmed-article:15871635pubmed:meshHeadingpubmed-meshheading:15871635...lld:pubmed
pubmed-article:15871635pubmed:year2005lld:pubmed
pubmed-article:15871635pubmed:articleTitlePharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.lld:pubmed
pubmed-article:15871635pubmed:affiliationRoche Products Ltd, Welwyn Garden City, UK.lld:pubmed
pubmed-article:15871635pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15871635pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:15871635pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:15871635pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15871635lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15871635lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15871635lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15871635lld:pubmed